Abivax SA (ABVX)

Abivax Cash Flow Statement

Financials in millions EUR. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-147.74	-147.74	-60.74	-42.45
Depreciation & Amortization	0.71	0.71	0.49	0.3
Share-Based Compensation	8.18	8.18	-1.16	0.83
Other Operating Activities	41.72	41.72	7.48	-3.73
Operating Cash Flow	-97.13	-97.13	-53.94	-45.05
Capital Expenditures	-0.27	-0.27	-0.32	-0.05
Acquisitions	-1.62	-1.62	-11.8	-6.18
Change in Investments	-8.61	-8.61	0.08	-0.01
Other Investing Activities	2.4	2.4	0.02	-
Investing Cash Flow	-8.1	-8.1	-12.03	-6.23
Share Issuance / Repurchase	353.39	353.39	46.37	69.68
Debt Issued / Paid	15.13	15.13	-6.87	19.06
Other Financing Activities	-33.23	-33.23	-7.29	-6.06
Financing Cash Flow	335.29	335.29	32.21	82.68
Exchange Rate Effect	-5.07	-5.07	0	0
Net Cash Flow	224.99	224.99	-33.75	31.4
Free Cash Flow	-97.4	-97.4	-54.26	-45.1
Free Cash Flow Margin	-2107.66%	-2107.66%	-1183.92%	-377.02%
Free Cash Flow Per Share	-2.26	-2.26	-2.84	-2.92

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).